<p>Myopia is a refractive error in which distant objects appear blurry while near objects are seen clearly. High myopia involves more severe nearsightedness and increases the risk of complications like myopic macular degeneration (MMD), retinal detachment, and posterior staphyloma, all of which can lead to permanent vision loss.</p>
<p>&nbsp;</p>
<p>The progression from myopia to pathological myopia can result in MMD, a condition in which the macula, the part of the retina responsible for detailed vision, degenerates. This is due to structural changes like an elongated eyeball and thinning of the choroid, which makes the macula more vulnerable. MMD is marked by staphyloma, lacquer cracks, Fuchs&rsquo; spot, or chorio-retinal atrophy in the posterior retina.</p>
<h2><strong>Myopic Macular Degeneration Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Myopic Macular Degeneration in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Total Diagnosed Prevalent Cases&nbsp;</li>
<li>Gender-specific Diagnosed Prevalent Cases</li>
<li>Total Diagnosed Prevalent cases of myopic choroidal neovascularization</li>
</ul>
<h2><span style="text-decoration: underline;"><a href="https://www.delveinsight.com/report-store/myopic-macular-degeneration-epidemiology-forecast"><strong>Myopic Macular Degeneration Epidemiology</strong></a></span></h2>
<ul>
<li>The diagnosed Myopic Macular Degeneration prevalent population in the 7MM was ~4.1 million in 2022.</li>
<li>The diagnosed prevalence of Myopic Macular Degeneration in the United States was ~1.1 million in 2022.</li>
<li>Among the 7MM, Japan accounted for the highest number of Myopic Macular Degeneration cases, with ~2 million diagnosed cases in 2022.</li>
</ul>
<h2><span style="text-decoration: underline;"><a href="https://www.delveinsight.com/report-store/myopic-macular-degeneration-market"><strong>Myopic Macular Degeneration Market</strong></a></span></h2>
<p>In the 7MM, the Myopic Macular Degeneration market mainly consisted of anti-VEGF therapies and standard of care, which generated nearly USD 734 million in 2022.</p>
<h2>Myopic Macular Degeneration Market Drivers</h2>
<ul>
<li>Rising prevalence of myopia globally, especially in East Asia.</li>
<li>Advancements in treatment options like anti-VEGF and photodynamic therapy.</li>
<li>Increased awareness and early diagnosis leading to more treatments.</li>
<li>Aging population contributing to higher cases of MMD.</li>
</ul>
<h2>Myopic Macular Degeneration Market Barriers</h2>
<ul>
<li>High treatment costs, limiting accessibility.</li>
<li>Lack of awareness in some regions leading to delays in diagnosis.</li>
<li>Treatment side effects discouraging patient compliance.</li>
<li>Limited access to specialized ophthalmic care in rural areas.</li>
</ul>
<h2><strong>Myopic Macular Degeneration Emerging Drugs</strong></h2>
<p>The emerging drugs of the Myopic Macular Degeneration market are</p>
<ul>
<li>VABYSMO (faricimab)</li>
</ul>
<p>And others.</p>
<h2><strong>Myopic Macular Degeneration Key Players</strong></h2>
<p>The key players in the Myopic Macular Degeneration market are</p>
<ul>
<li>Roche</li>
</ul>
<p>And others.</p>

Myopic Macular Degeneration Market Infographics

Myopic Macular Degeneration Market Infographic

Myopic Macular Degeneration Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.